Reporting rates of adverse reactions to specialty care medicines exhibit a direct positive correlation with patient exposure: A lack of evidence for the Weber effect

Abstract

The classical Weber effect describes an increase in adverse reaction (AR) reports after medicinal product authorisation, with a peak in AR reporting at the end of the second year followed by a decline, despite increasing patient exposure. The present study aimed to evaluate the validity of the Weber effect in the context of authorised medicines in a specialty care setting. Methods: Using 6-monthly sales data as a proxy for exposure, the exposure-adjusted reporting rates for AR reports for 10 selected specialty care medicines were plotted against time. These data were also evaluated based on the source of report (solicited or unsolicited) and the nature of the AR contained within the reports (listed or unlisted). Unsolicited reports were analysed against sales volumes. Goodness of fit (R 2) was calculated and the trend representing the highest R 2 was selected. Results: Study data comprised a total of 1 222 852 AR reports for 10 specialty care medicines. Amongst all of the products evaluated, none of the associated data represented reporting patterns entirely consistent with the classical Weber effect (see Figure 1). The results, however, showed a systemic direct correlation between AR reporting and sales volumes, especially throughout the first 5 years postauthorisation. Conclusion: The study not only presents evidence of the absence of the Weber effect with specialty care medicines but also provides a substantial evidence of linear AR reporting correlating with sales volumes, especially during the first 5 years after marketing.

Investigating the link between drug consumption and adverse events reporting in France

“…Indeed, in our study, the date of labeling was not significantly associated with the adverse event reporting rate in pharmacovigilance databases. This finding is consistent with previous studies exploring Weber's effects, which have found no evidence of this phenomenon in recent years [3]. Surprisingly, the reporting rate of certain drugs, such as desloratadine, was particularly low.…”

“…While disproportionality analyses allow the detection of higher than expected associations between adverse events and drugs, the lack of patient exposure data and the selective reporting of adverse events do not allow the calculation of adverse event incidence rates [2]. Yet, despite this selective reporting, a recent study suggested that the total number of adverse events reported for a given drug is correlated to drug exposure without evidence of the Weber effect or other time-varying reporting bias [3]. This total number of reported adverse events cannot be used as a proxy for drug exposure per se, given drugs display heterogeneous safety profiles, different indications, and exposed populations, but we hypothesized that it could be the case among a drug class.…”

Identification of different side effects between PARP inhibitors and their polypharmacological multi‐target rationale

“…Rucaparib, niraparib and talazoparib are all black triangle drugs and all suspected ADRs need to be reported regardless of severity. There is likely to be a significant under‐reporting of suspected ADRs 50,51 …”

Status and strategies of college English teaching using adaptive deep learning from the perspective of multiculturalism

“…Combining EC and DL can shorten the data transmission time and improve security performance. The advent of the “Internet +” era has provided an opportunity for the rapid development of Mobile Intelligence (MI) and EC ( Han et al, 2019 ; Modgill et al, 2020 ). In particular, EC is a technology developed under the background of high bandwidth, time-sensitive, and integrated Internet of Things (IoT), much different from Cloud Computing (CC).…”